Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma

  • STATUS
    Not Recruiting
  • participants needed
    45
  • sponsor
    Millennium Pharmaceuticals, Inc.
Updated on 18 June 2021
Investigator
Takeda Study Registration Call Center
Primary Contact
Semmelweis Egyetem (9.3 mi away) Contact
+39 other location
measurable disease
brentuximab vedotin

Summary

This is a single-arm, open-label, multicenter, phase 4 clinical trial to evaluate the efficacy and safety of brentuximab vedotin as a single agent in patients with relapsed or refractory Systemic Anaplastic Large Cell Lymphoma (SALCL).

Details
Condition anaplastic large cell lymphoma
Treatment brentuximab vedotin
Clinical Study IdentifierNCT01909934
SponsorMillennium Pharmaceuticals, Inc.
Last Modified on18 June 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note